Opinion|Videos|October 25, 2024
MRD Negativity as a Trial Outcome and Its Use in Clinical Practice
Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.
Advertisement
Episodes in this series
- Dr Ajai Chari to Dr Raje: What are your thoughts on minimal residual disease negativity as a primary outcome?
- Dr Ajai Chari to Dr Rossi: For patients who are eligible for transplantation but decline, what is your treatment approach for this patient population? Do you have a preferred induction regimen?
Advertisement
Related to this article
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
2
CNS Control and Daily Tolerability Guide Treatment Sequencing in HER2-Mutated NSCLC
3
Tabelecleucel BLA Is Resubmitted to FDA for EBV+ Post-Transplant Lymphoproliferative Disease
4
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
5